Page 22 - Read Online

Ossoliński et al. J Cancer Metastasis Treat 2019;5:1 Journal of Cancer
DOI: 10.20517/2394-4722.2018.63 Metastasis and Treatment

Original Article Open Access

Mass spectrometry-based metabolomic profiling of
prostate cancer - a pilot study

Krzysztof Ossoliński , Joanna Nizioł , Adrian Arendowski , Anna Ossolińska , Tadeusz Ossoliński ,
1#
1
1
2#
2
Jakub Kucharz , Paweł Wiechno , Tomasz Ruman 2
3
3
1 Department of Urology, John Paul II Hospital, Kolbuszowa 36-100, Poland.
2 Faculty of Chemistry, Rzeszów University of Technology, Rzeszów 35-959, Poland.
3 Department of Urooncology, Institute of Oncology, Warsaw 02-781, Poland.
# Authors contributed equally.
Correspondence to: Dr. Tomasz Ruman, Faculty of Chemistry, Rzeszów University of Technology, al. Powstanców Warszawy 6,
Rzeszów 35-959, Poland. E-mail: tomruman@prz.edu.pl
How to cite this article: Ossoliński K, Nizioł J, Arendowski A, Ossolińska A, Ossoliński T, Kucharz J, Wiechno P, Ruman T. Mass
spectrometry-based metabolomic profiling of prostate cancer - a pilot study. J Cancer Metastasis Treat 2019;5:1.
http://dx.doi.org/10.20517/2394-4722.2018.63
Received: 22 Sep 2018 First Decision: 19 Nov 2018 Revised: 17 Dec 2018 Accepted: 19 Dec 2018 Published: 8 Jan 2019

Science Editor: Bing-Liang Fang Copy Editor: Cui Yu Production Editor: Huan-Liang Wu

Abstract
Aim: Prostate cancer (PCa) is the most commonly diagnosed non-skin cancer among men. Serum prostate-
specific antigen level is used as a standard PCa biomarker for over 20 years. However, it has only 33% specificity
and 86% sensitivity (for the cutoff value for prostate biopsy of > 4 ng/mL). This leads to overdiagnosis and
overtreatment. In-depth insight into PCa metabolomics enables discovery of novel PCa biomarkers.

Methods: Metabolomic alternation in PCa serum, urine and interstitial fluid was examined using gold-
nanoparticle-based laser mass spectrometry imaging. This study included 5 patients who underwent prostate
biopsy with positive result, 5 patients with negative result and 10 healthy controls.

Results: Over two hundred differentiating metabolites (87 in urine, 54 in serum and 78 in interstitial fluid) were
detected. Four, twenty two and ten metabolites from urine, serum and interstitial fluid respectively showed
statistical significant differential abundance between cancer and control group.

Conclusion: Comprehensive metabolomic profile of PCa has been identified. Out of 36 metabolites, 20 were
identified and should be further evaluated in clinical trials as a potential PCa biomarker. Urine concentration of
triglyceride (12:0/20:1) showed over 10 times higher abundance in PCa samples in comparison to healthy controls
and is considered the most promising potential biomarker.

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jcmtjournal.com